News
Zacks Investment Research on MSN18h
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...
Zacks Investment Research on MSN22h
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?BioMarin Pharmaceutical BMRN shares ended the last trading session 6.3% higher at $59.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time ...
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) on April 3 and set a price target of ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...
StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating ...
Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback